Plasma exchange with mPSL-PULSE therapy against Isaacs' syndrome

Plasma exchange with mPSL-PULSE therapy against Isaacs' syndrome - Plasma exchange with mPSL-PULSE therapy against Isaacs' syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015440

Enrollment

Registered

2014-10-15

Start date

2014-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Isaacs&#39

Interventions

The set therapy consists of 1 plasmapheresis followed by mPSL-PULSE, which is performed by serial intravenous injection of 1.0 g methylprednisolone immediately after plasmapheresis and on the morning

s symptoms. Plasmapheresis is performed using the plasma-exchange method. The set therapy during hospitalization can also consist of oral prednisolone not exceeding 20 mg/day in addition to mPSL-PULSE

10 mg/day is needed, the patient is recommended to be hospitalized and undergo the set therapy again.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient is applicable to definite or probable of provisional diagnostic criteria for Isaacs' syndrome (Watanabe, Clinical Neurology 2013;53:1067-1070).

Exclusion criteria

Exclusion criteria: Severe infection.

Design outcomes

Primary

Measure	Time frame
MG-ADL score	—

Secondary

Measure	Time frame
modified Rankin scale myotonia score %VC	—

Countries

Japan

Contacts

Public ContactTakanari Toyoda

Nagoya City University Graduate School of Medical Sciences Neurology

ttoyoda@med.nagoya-cu.ac.jp052-851-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Plasma exchange with mPSL-PULSE therapy against Isaacs&#39; syndrome